Home > Oncology > BCC 2019 > St. Gallen Consensus > St. Gallen Consensus – Endocrine Therapy in Premenopausal Patients

St. Gallen Consensus – Endocrine Therapy in Premenopausal Patients

Conference
BCC 2019
Trial
SOFT, TEXT

The first question the panel had to answer on this topic was the ideal cut-off – in terms of percentage of ER-positive tumour cells – to prescribe endocrine therapy. There was no clear consensus on this topic: 30% of the panellists voted for >1%, 4% voted for >5%, 39% voted for >10%, while 25% took the view that there is no clear answer. Recently, updates were presented of the SOFT and TEXT trial [1] showing that among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. Based on these results, a majority of the panellists (68%) took the view that premenopausal patients with an ER-positive tumour who are getting adjuvant chemotherapy are candidate for ovarian function suppressive (OFS) therapy. Also in line with the SOFT and...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on